Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.

Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, Barcellos-Hoff MH.

Clin Cancer Res. 2011 Nov 1;17(21):6754-65. doi: 10.1158/1078-0432.CCR-11-0544. Epub 2011 Oct 25.

2.

Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non-small-cell lung cancer cells in vitro and in vivo.

Du S, Bouquet S, Lo CH, Pellicciotta I, Bolourchi S, Parry R, Barcellos-Hoff MH.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):91-9. doi: 10.1016/j.ijrobp.2014.09.026.

PMID:
25835621
3.

Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.

Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U, Lahn M, Huber PE.

Cancer Res. 2011 Dec 1;71(23):7155-67. doi: 10.1158/0008-5472.CAN-11-1212. Epub 2011 Oct 17.

4.

Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress.

Kirshner J, Jobling MF, Pajares MJ, Ravani SA, Glick AB, Lavin MJ, Koslov S, Shiloh Y, Barcellos-Hoff MH.

Cancer Res. 2006 Nov 15;66(22):10861-9. Epub 2006 Nov 6.

5.

Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.

Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM, Barcellos-Hoff MH.

Cancer Res. 2012 Aug 15;72(16):4119-29. doi: 10.1158/0008-5472.CAN-12-0546. Epub 2012 Jun 12.

6.

Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.

Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM.

Bone. 2012 Mar;50(3):695-703. doi: 10.1016/j.bone.2011.11.022. Epub 2011 Dec 7.

7.

Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

Zhang M, Herion TW, Timke C, Han N, Hauser K, Weber KJ, Peschke P, Wirkner U, Lahn M, Huber PE.

Neoplasia. 2011 Jun;13(6):537-49.

8.

Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.

Maggiorella L, Deutsch E, Frascogna V, Chavaudra N, Jeanson L, Milliat F, Eschwege F, Bourhis J.

Cancer Res. 2003 May 15;63(10):2513-7.

9.

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.

Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ.

Mol Cancer Ther. 2008 Apr;7(4):829-40. doi: 10.1158/1535-7163.MCT-07-0337.

10.

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE.

Clin Cancer Res. 2011 Sep 1;17(17):5638-48. doi: 10.1158/1078-0432.CCR-11-0650. Epub 2011 Jul 28.

11.

An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.

Rausch MP, Hahn T, Ramanathapuram L, Bradley-Dunlop D, Mahadevan D, Mercado-Pimentel ME, Runyan RB, Besselsen DG, Zhang X, Cheung HK, Lee WC, Ling LE, Akporiaye ET.

Anticancer Res. 2009 Jun;29(6):2099-109.

12.

Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.

Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z, Yang Z, Zhang Y, Shi T, Luo J, Liu M.

J Natl Cancer Inst. 2013 Jan 2;105(1):47-58. doi: 10.1093/jnci/djs485. Epub 2012 Nov 24.

PMID:
23178439
13.

Inhibition of TGFβ type I receptor activity facilitates liver regeneration upon acute CCl4 intoxication in mice.

Karkampouna S, Goumans MJ, Ten Dijke P, Dooley S, Kruithof-de Julio M.

Arch Toxicol. 2016 Feb;90(2):347-57. doi: 10.1007/s00204-014-1436-y. Epub 2015 Jan 8.

PMID:
25566828
14.

EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.

Son JY, Park SY, Kim SJ, Lee SJ, Park SA, Kim MJ, Kim SW, Kim DK, Nam JS, Sheen YY.

Mol Cancer Ther. 2014 Jul;13(7):1704-16. doi: 10.1158/1535-7163.MCT-13-0903. Epub 2014 May 9.

15.

An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.

Park CY, Min KN, Son JY, Park SY, Nam JS, Kim DK, Sheen YY.

Cancer Lett. 2014 Aug 28;351(1):72-80. doi: 10.1016/j.canlet.2014.05.006. Epub 2014 Jun 2.

PMID:
24887560
16.

Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.

Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M.

Mol Cancer. 2010 May 26;9:122. doi: 10.1186/1476-4598-9-122.

17.

LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.

Gao Y, Shan N, Zhao C, Wang Y, Xu F, Li J, Yu X, Gao L, Yi Z.

Int J Clin Exp Pathol. 2015 May 1;8(5):4923-32. eCollection 2015.

18.

Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.

Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K.

Mol Cancer Ther. 2009 Jun;8(6):1589-95. doi: 10.1158/1535-7163.MCT-09-0038. Epub 2009 Jun 9.

19.

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.

Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL.

J Clin Invest. 2013 Mar;123(3):1348-58. doi: 10.1172/JCI65416. Epub 2013 Feb 8.

20.

Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways.

Tiedemann K, Hussein O, Sadvakassova G, Guo Y, Siegel PM, Komarova SV.

J Biol Chem. 2009 Nov 27;284(48):33662-70. doi: 10.1074/jbc.M109.010785. Epub 2009 Sep 30.

Supplemental Content

Support Center